Celmatix Launches MyFertility Compass to Give Women Better Insights into Their Family Building Journey

Today, Celmatix, the next-generation women’s health company, announced
the launch of MyFertility Compass™, an online tool that helps women
understand their personalized likelihoods of having a baby, with or
without the use of common fertility treatments including in vitro
fertilization. MyFertility Compass leverages world-class science to
educate women about the factors that could influence their fertility
while providing data-driven projections to help women better partner
with their physicians on their family building journeys.

“We learned in our research that many women do not speak to their
physicians when they are on their family building journeys and instead
consult the internet. Our mission has always been to help women be more
proactive about their fertility and health through better science and
personalization,” said Dr. Piraye Yurttas Beim, founder and CEO of
Celmatix. “It has been tremendously rewarding to see how our Polaris®
platform has impacted over 90,000 patients at fertility centers and how
our Fertilome® genetic test is bringing true personalized medicine to
reproductive health. Both of these products are currently primarily
accessed through specialist physicians so we wanted to build a tool that
would impact more women, earlier in their journeys.”

MyFertility Compass is free and easy to use. When a woman who is
currently trying to get pregnant visits www.myfertilitycompass.io,
she will be asked to provide her age and to answer questions about her
lifestyle and health that may impact her fertility. Using that
information, MyFertility Compass generates a personalized fertility
report. For women under 35 who have been trying for more than a year,
and women over 35 who have been trying for at least six months, their
personalized report will also include their estimated likelihoods of
success under the care of a physician using basic or more advanced
fertility treatments.

The models that power MyFertility Compass are based on a combination of
peer-reviewed scientific studies and Celmatix’s own proprietary
predictive models, which have been developed using a structured real
world evidence dataset of nearly 1 million fertility treatment outcomes.

“As an OBGYN physician and fertility specialist, I know that many times
women on their family building journeys worry too soon or more commonly
not soon enough,” said Linda C. Giudice, MD, PhD, Distinguished
Professor and the Robert B. Jaffe MD Endowed Professor in the
Reproductive Sciences in the Department of Obstetrics, Gynecology and
Reproductive Sciences at the University of California, San Francisco
(UCSF), as well as a member of the Celmatix Scientific Advisory Board.
“MyFertility Compass is an innovative and valuable resource that
empowers women to assess their fertility potential and pathways to
optimize achieving their goals of family building. Data-driven tools
like MyFertility Compass can have a big impact by giving women more
personalized and relevant insights. With the demographic trends of women
waiting until later in life to start or expand their families, directing
women to the right care at the right time is more important than ever.”

To learn more about your fertility journey, visit www.myfertilitycompass.io.
For more information on Celmatix, visit www.celmatix.com.

About Celmatix Inc.

Celmatix is a next-generation women’s health company transforming
reproductive health care through genomics and big data. Founded in 2009
and based in New York City, Celmatix is disrupting how women approach
their lifelong fertility journey by empowering them and their physicians
with more personalized information. The company’s research-driven
products include the Fertilome® test, the world’s first multigene panel
test that reveals what a woman’s DNA says about her reproductive health,
Polaris®, a real-time predictive analytics platform in use at leading
fertility clinics across the U.S., which helps physicians optimize
patient outcomes and improve the patient experience, and MyFertility
Compass™, a data-driven education tool that gives women who are
currently trying to conceive insights into their fertility potential.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005189/en/

Leave a Comment